Verweij J - Search Results

1

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.

Loos WJ, Gelderblom H, Verweij J, van Boven-van Zomeren DM, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: verweij j. Anticancer Drugs. 2003 Mar;14(3):227-32. doi: 10.1097/00001813-200303000-00006. Anticancer Drugs. 2003. PMID: 12634617 Clinical Trial.

2

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Mathijssen RH, et al. Among authors: verweij j. J Clin Oncol. 2002 Jan 1;20(1):81-7. doi: 10.1200/JCO.2002.20.1.81. J Clin Oncol. 2002. PMID: 11773157

3

Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.

Loos WJ, van Zomeren DM, Gelderblom H, Verweij J, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: verweij j. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):99-105. doi: 10.1016/s0378-4347(01)00432-7. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 11820300

4

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.

Loos WJ, Szebeni J, ten Tije AJ, Verweij J, van Zomeren DM, Chung KN, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: verweij j. Anticancer Drugs. 2002 Aug;13(7):767-75. doi: 10.1097/00001813-200208000-00012. Anticancer Drugs. 2002. PMID: 12187334

5

Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Mathijssen RH, et al. Among authors: verweij j. Curr Cancer Drug Targets. 2002 Jun;2(2):103-23. doi: 10.2174/1568009023333890. Curr Cancer Drug Targets. 2002. PMID: 12188913 Review.

6

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J. Smorenburg CH, et al. Among authors: verweij j. J Clin Oncol. 2003 Jan 15;21(2):197-202. doi: 10.1200/JCO.2003.01.058. J Clin Oncol. 2003. PMID: 12525510 Clinical Trial.

7

Distribution of paclitaxel in plasma and cerebrospinal fluid.

Gelderblom H, Baker SD, Zhao M, Verweij J, Sparreboom A. Gelderblom H, et al. Among authors: verweij j. Anticancer Drugs. 2003 Jun;14(5):365-8. doi: 10.1097/00001813-200306000-00007. Anticancer Drugs. 2003. PMID: 12782943 Clinical Trial.

8

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.

de Jong FA, Mathijssen RH, de Bruijn P, Loos WJ, Verweij J, Sparreboom A. de Jong FA, et al. Among authors: verweij j. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):383-8. doi: 10.1016/s1570-0232(03)00574-9. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 14522044

9

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.

Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Loos WJ, et al. Among authors: verweij j. Clin Pharmacol Ther. 2003 Oct;74(4):364-71. doi: 10.1016/S0009-9236(03)00222-4. Clin Pharmacol Ther. 2003. PMID: 14534523

10

Limited cerebrospinal fluid penetration of docetaxel.

ten Tije AJ, Loos WJ, Zhao M, Baker SD, Enting RH, van der Meulen H, Verweij J, Sparreboom A. ten Tije AJ, et al. Among authors: verweij j. Anticancer Drugs. 2004 Aug;15(7):715-8. doi: 10.1097/01.cad.0000136882.19552.8f. Anticancer Drugs. 2004. PMID: 15269603

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

927 results

Search Page

Filters